{
    "body": "What is the function of Oseltamivir when administered during flu?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23810646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23794010", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12058885", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22754968", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19273546", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10708809", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22666678", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27341844", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20843284", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20537158", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19453477", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18457919", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12825569", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23208833", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24825206", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19523442", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21677258", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27490658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20056566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16838232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26049014", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10866439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19457254", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20218988", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23214216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15750458", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20635821", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23997307", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19557131", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10536125", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23100798", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16494733", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24366750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20499654", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24524404", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20885781"
    ], 
    "ideal_answer": [
        "Oseltamivir (has known by its brand name 'Tamiflu') is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. Oseltamivir is the first orally active neuraminidase inhibitor and it is an antiviral drug for the treatment of Swine Flu."
    ], 
    "concepts": [
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4242246", 
        "http://www.biosemantics.org/jochem#4242246", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053139", 
        "http://www.disease-ontology.org/api/metadata/DOID:8469", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4242585", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007251", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007252"
    ], 
    "type": "summary", 
    "id": "589ae59c78275d0c4a000036", 
    "snippets": [
        {
            "offsetInBeginSection": 796, 
            "offsetInEndSection": 861, 
            "text": "All patients were given specific antiviral therapy (oseltamivir).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23214216", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 614, 
            "text": "Oseltamivir (has known by its brand name 'Tamiflu') is a prodrug, requiring ester hydrolysis for conversion to the active form, Oseltamivir carboxylate. Oseltamivir was the first orally active neuraminidase inhibitor commercially developed by US based Gilead Sciences and is currently marketed by F. Hoffmann-La Roche (Roche). Oseltamivir is an antiviral drug which works by blocking the function of the viral neuraminidase protein. US FDA approved Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, Oseltamivir is the only first line defense drug available for the treatment of Swine Flu. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 512, 
            "offsetInEndSection": 705, 
            "text": "The latter is the binding cavity for 3 currently used neuraminidase inhibitors: oseltamivir (Tamiflu), zanamivir (Relenza) and peramivir; thus, the drugs should remain effective for treatment. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19457254", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2829, 
            "offsetInEndSection": 3050, 
            "text": "Though therapeutic dose of oseltamivir was given as antiviral treatment for the early therapy, and other therapeutic measures such as energetic respiratory and circulatory support, and immunosuppressant therapy were given", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24524404", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 92, 
            "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is widely used for treatment of influenza.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19273546", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 131, 
            "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is effective for treating both seasonal flu and H5N1 influenza A virus infection.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457919", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 229, 
            "text": "BACKGROUND: Oseltamivir phosphate (OP; Tamiflu) is a prodrug of the anti-influenza neuraminidase inhibitor oseltamivir carboxylate (OC) and has been developed for the treatment and prevention of both A and B strains of influenza.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20056566", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 220, 
            "text": "Oseltamivir (Tamiflu) is currently the frontline antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase, a flu protein responsible for the release of newly synthesized virions.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885781", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 138, 
            "text": "Oseltamivir (Tamiflu) is the most important antiviral drug available and a cornerstone in the defence against a future influenza pandemic.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19557131", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 454, 
            "offsetInEndSection": 546, 
            "text": "The country where oseltamivir is used most is Japan, where it is used to treat seasonal flu.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19557131", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1353, 
            "offsetInEndSection": 1449, 
            "text": "Oseltamivir safety and tolerability were verified in patients with new variant infection A/H1N1.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499654", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 620, 
            "text": "To investigate oseltamivir and oseltamivir carboxylate pharmacokinetics in critically ill patients who were receiving continuous venovenous hemodialysis (CVVHD) and/or extracorporeal membrane oxygenation (ECMO).Prospective, open-label, pharmacokinetic study.Intensive care units of an academic medical center.Thirteen critically ill patients aged 13\u00a0years or older with suspected or confirmed H1N1 influenza who had a prescription for oseltamivir and were concurrently receiving CVVHD and/or ECMO between October 2009 and January 2010.Oseltamivir 150\u00a0mg was administered nasogastrically or nasoenterically every 12\u00a0hours", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23208833", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 186, 
            "offsetInEndSection": 748, 
            "text": "The study included 3351 patients in whom influenza had been diagnosed by use of an antigen detection test kit.Oseltamivir was administered to 1818 patients with influenza A and 1485 patients with influenza B. No anti-influenza drugs were administered to 21 patients with influenza A or to 27 patients with influenza B. Patients receiving oseltamivir therapy were divided into 4 groups according to the time between the onset of fever (temperature, > or = 37.5 degrees C) and administration of the first dose of oseltamivir (0-12 h, 13-24 h, 25-36 h, and 37-48 h)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16838232", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 331, 
            "offsetInEndSection": 856, 
            "text": "To clarify the usefulness of oseltamivir in the elderly we administered oseltamivir to all residents when an influenza A outbreak occurred in a nursing home.Sixty-eight residents in the nursing home were investigated in which the influenza A outbreak occurred; 32 residents had fever and 28 residents were positive for influenza A with direct enzyme immunoassay.Oseltamivir was administered at 75 mg twice daily for 5 days to all residents.Oseltamivir almost inhibited symptom onset in the influenza A-positive afebrile group", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12058885", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 101, 
            "offsetInEndSection": 261, 
            "text": "Oseltamivir was administered to patients with influenza like illness and confirmed influenza, while their close contacts were given oseltamivir prophylactically", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16494733", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 121, 
            "text": "Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19523442", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 131, 
            "text": "Evaluation of treatment with Oseltamivir during the 2009 H1N1 (swine flu) pandemic: the problem of incomplete clinical information.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22754968", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 133, 
            "text": "Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10708809", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 124, 
            "text": "Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15750458", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 107, 
            "offsetInEndSection": 336, 
            "text": "Oseltamivir (Tamiflu) is a potent and selective antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase (NA), a flu protein responsible for the release and spread of the progeny virions.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23794010", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 327, 
            "offsetInEndSection": 432, 
            "text": "Oseltamivir is an antiviral drug which works by blocking the function of the viral neuraminidase protein.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 334, 
            "offsetInEndSection": 432, 
            "text": "Neuraminidase (NA) inhibitors (Oseltamivir and Zanamivir) are presently used as an anti-flu drugs.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 433, 
            "offsetInEndSection": 613, 
            "text": "US FDA approved Oseltamivir for prophylaxis of uncomplicated influenza A and B. Currently, Oseltamivir is the only first line defense drug available for the treatment of Swine Flu.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 739, 
            "offsetInEndSection": 872, 
            "text": "Oseltamivir and Zanamivir have good number of interactions with H1N1 2009 virus and the scoring function also support to this result.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1323, 
            "offsetInEndSection": 1480, 
            "text": "The number of interaction and scoring function shows that Oseltamivir and Zanamivir will be able to effectively control the present pandemic H1N1 virus 2009.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 233, 
            "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is effective for treating both seasonal flu and H5N1 influenza A virus infection. Oseltamivir is generally well tolerated, and its most common adverse effects are nausea and vomiting.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457919", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 322, 
            "text": "Oseltamivir (Tamiflu) is currently the frontline antiviral drug employed to fight the flu virus in infected individuals by inhibiting neuraminidase, a flu protein responsible for the release of newly synthesized virions. However, oseltamivir resistance has become a critical problem due to rapid mutation of the flu virus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885781", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 340, 
            "offsetInEndSection": 592, 
            "text": "Approximately 1.4% of tested isolates are oseltamivir resistant. We report a patient with an underlying hematological malignancy who was hospitalized with influenza A (H1N1) swine-origin and whose strain developed oseltamivir resistance during therapy.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20218988", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 357, 
            "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is widely used for treatment of influenza. Because abnormal behaviors have been observed in some Japanese teenagers following oseltamivir use, its safety has been questioned. Oseltamivir is known to alter neuronal function and behavior in animals, particularly when administered in combination with ethanol.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19273546", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 462, 
            "text": "Oseltamivir (Tamiflu), a neuraminidase inhibitor, is effective for treating both seasonal flu and H5N1 influenza A virus infection. Oseltamivir is generally well tolerated, and its most common adverse effects are nausea and vomiting. However, neuropsychiatric behaviors including jumping and falling from balconies by young patients being treated by oseltamivir have been reported from Japan; this has led to warnings against its prescribing by many authorities.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18457919", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 221, 
            "offsetInEndSection": 322, 
            "text": "However, oseltamivir resistance has become a critical problem due to rapid mutation of the flu virus.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20885781", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 900, 
            "offsetInEndSection": 1186, 
            "text": "We observed also 10 infections A/H1N1 influenza during pregnancy, with good oseltamivir tolerance and without recent perinathal complications.CONCLUSIONS: Among 109 individuals with swine flu influenza, 67% have not complicated clinical manifestation and they recovered during 3-4 days.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20499654", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1323, 
            "offsetInEndSection": 1481, 
            "text": "The number of interaction and scoring function shows that Oseltamivir and Zanamivir will be able to effectively control the present pandemic H1N1 virus 2009..", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23100798", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1446, 
            "offsetInEndSection": 1516, 
            "text": "Most reported that oseltamivir was an effective treatment for the flu.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490658", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 582, 
            "offsetInEndSection": 658, 
            "text": "It is needed to perform surveillance on oseltamivir resistance in swine flu.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22666678", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 100, 
            "text": "The neuraminidase (NA) of influenza virus is the target of anti-flu drugs oseltamivir and zanamivir.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19523442", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 330, 
            "offsetInEndSection": 468, 
            "text": "According to one trial, oseltamivir was moderately effective as a prophylactic for close contacts of 'flu cases (6.6% in absolute values).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12825569", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 53, 
            "text": "Oseltamivir: a first line defense against swine flu.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20843284", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 2312, 
            "offsetInEndSection": 2430, 
            "text": "Oseltamivir administered daily for six weeks by the oral route is safe and effective for the prevention of influenza..", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10536125", 
            "endSection": "abstract"
        }
    ]
}